StockNews.AI
CLDX
StockNews.AI
8 days

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

1. Celldex to present Phase 2 study data on barzolvolimab. 2. Webcast scheduled for June 12 at 6:00 pm ET. 3. Data focuses on chronic spontaneous urticaria and angioedema. 4. Lead investigator, Dr. Martin Metz, will present findings. 5. Results could impact market perception of CLDX’s pipeline.

4 mins saved
Full Article

FAQ

Why Bullish?

Presenting encouraging data at major congress can boost investor confidence, similar to past successful presentations affecting stock prices positively.

How important is it?

Key data presentation on a flagship therapy could lead to price action as investors reassess CLDX’s potential.

Why Short Term?

Immediate market reaction expected post-webcast, particularly if positive data is presented; historical presentations have led to quick gains.

Related Companies

VRTXAMGNBMRN
Company to host webcast on Thursday, June 12 at 6:00 pm ET June 10, 2025 16:01 ET  | Source: Celldex Therapeutics, Inc. HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12th at 6:00 pm ET to discuss the data. Phase 2 CSU 76 Week Efficacy and Tolerability Data Company Webcast and Conference CallDate & Time: Thursday, June 12th at 6:00 pm ET/11:00 pm BSTPresenters: Company representatives and Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU studyWebcast Access: Please visit the Events section on the Investor Relations page of Celldex's website to register for the webcast. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. EAACI Presentation Session Date & Time: Friday, June 13th at 9:12 am BST/4:12 am ETLate Breaking Oral Presentation 100227: Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous UrticariaPresenting Author: Ana Maria Giménez-Arnau, MD, PhD, Associate Professor of DermatologyAutonomous University and Pompeu Fabra University Phase 2 CSU 52 Week Angioedema Data EAACI Session Date & Time: Saturday, June 14th at 3:48 pm BST/10:48 am ETOral Presentation 000588: Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of TreatmentPresenting Author: Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@celldex.com Patrick TillMeru Advisors(484) 788-8560ptill@meruadvisors.com

Related News